Patent ID: 9655950
Date: 2017-05-23
CPC Classifications: A61K,A61P,G01N

Claim:
1. A method of treating a subject suffering from cutaneous T-cell lymphoma with interferon-α, by comparing activation levels of myeloid-derived suppressor cells in the subject in response to a test dose of interferon-α, said method comprising: (i) determining a first activation level of myeloid-derived suppressor cells in the subject; (ii) administering a test dose of interferon-α to the subject; (iii) determining a second activation level of myeloid-derived suppressor cells in the subject after administering the test dose of interferon-α to the subject; (iv) comparing the first activation level to the second activation level; (v) determining that the subject has a greater likelihood of benefiting from an interferon-α treatment when the second activation level is reduced compared to the first activation level; and (vi) where the second activation level is reduced compared to the first activation level, treating the subject with interferon-α.